This week, Sing Medical (“SMG”) caught my attention.
SMG has dropped 39% from $0.725 on 18 Jul 2017 to trade $0.440 on 3 Oct 2018. My personal guess is part of the fall may be attributable to
- a) Lower, or no earnings growth for some of the healthcare players in FY18F. However, this is likely not the case for SMG, as analysts believe SMG is on track for a minimum 40% growth in FY18F net profit. It is noteworthy that SMG already posted a 70% jump in 1HFY18 net profit;
- b) Reduction in the general PE valuations ascribed to the healthcare sector;
So, what caught my attention?
- a) Positive chart: SMG is testing its downtrend line established since 26 Jan 2018 (See Chart 1 below). Indicators such as OBV, RSI and MACD are strengthening. ADX has started to rise and last trades 22.6 on 3 Oct ...
...
